### Index

**A**
- Adalimumab, 115, 300
- Adherent-invasive *Escherichia coli* (AIEC), 46
- Adrenocorticotropic hormone (ACTH), 80
- American Gastroenterological Association (AGA) guidelines, 185
- 5-Aminosalicylic acid (5-ASA)
  - clinical presentation, 59–60
  - critical review, 63–64
  - NCCDS, 62
  - practice guidelines, 64
- Anal endosonography (AES), 218
- Antibiotics
  - Crohn’s disease, 130, 141
  - meta analysis, 134–135
  - pouchitis, 131, 142
  - ulcerative colitis, 131, 141–142
- Antineutrophil cytoplasmic antibodies (ANCA), 178
- Anti-*Saccharomyces cerevisiae* antibodies (ASCA), 153, 178, 232
- Appendectomy, 21
- Asacol®, 61, 63
- Azathioprine (AZA), 114–115, 184–185, 200
- Azathioprine/6-mercaptopurine (AZA and 6-MP)
  - CD
    - adverse events, 99–100
    - induction and maintenance therapy, 94, 96–97
    - metabolite levels monitoring, 98–99
    - TPMT genotype, 98–99
    - mechanism of action and metabolism, 94, 96
    - randomized-controlled and retrospective trials, 95
    - ulcerative colitis, 97–98

**B**
- Bacteroidetes, 45–46
- Balsalazide, 61
- Beclomethasone dipropionate (BDP), 75
- Biliary disease. See Primary sclerosing cholangitis (PSC)
- Biological therapy
  - controversies, 117–118
  - Crohn’s disease
    - adalimumab, 115
    - certolizumab pegol, 115
    - infliximab, 113–115
    - natalizumab, 115–116
    - immunogenicity, 112–113
    - infectious and neoplastic complication, 116–117
    - principles, 112
    - risks, 116–117
    - ulcerative colitis, 116
- Bone mineral density (BMD), 159
- Bowel-sparing procedures, 297
- Budesonide, 75

**C**
- Calprotectin, 137
- Capsule endoscopy (CE)
  - advantage, 235
  - diagnostic yield, 235–236
  - indications, 235
  - limitations, 236–237
  - vs. other diagnostic modalities, 235
  - scoring index, 237
  - small bowel Crohn’s disease, 235–236
- Certolizumab pegol, 115
- Chemoprophylaxis, 67
- Cholangiocarcinoma, 221
- Chromoendoscopy, 240–241
- Collagenous colitis, 263
Colonoscopy, 223
Colorectal cancer (CRC)
  biomarkers, 276
  chemoprevention, 275
  chromoendoscopy, 271, 272
  clinical manifestation, 266
  confocal laser endomicroscopy, 272
Crohn’s disease, 268–269
  narrow band imaging, 272, 273
  periodic surveillance colonoscopy, 271
  recommended guidelines, 273–274
  risk factors, 172
    dysplasia, 269–270
    strictures, 271
  ulcerative colitis
    incidence rate, 266–267
    risk factors, 267–268
Computed tomographic enterography (CTE)
  abnormal mural enhancement, 210
Crohn’s disease
  capsule endoscopy, 213–214
  extraenteric complications, 211–212
  factors, 209–210
  features, 242–243
  histopathological inflammation, 214
  stricture, 211
  diagnostic yield, 244
  findings, 243
  indications, 213
  limitations, 244
  MDCT, 209
  mural stratification, 211
  neutral contrast agent, 209
  role, 211
  SB examination, 242–243
  sensitivity and specificity, 213–214
  use of, 213
Confocal laser endomicroscopy (CLE)
  241, 272
Continent ileostomy, 171
Controlled ileal-release (CIR) formulation, 77
Corticosteroids (CS), 113, 196
  adverse effects, 81–88
Crohn’s disease
  CIR formulation, 77
  systemic agents, 79–81
  topical agents, 77–79
Crohn’s and Colitis Foundation of America, 273
Crohn’s disease (CD), 41
  adalimumab, 115
  aminosalicylates
    5-ASA, 62
    Asacol®, 63
    meta-analysis, 63–64
    Pentasa®, 63
    practice guidelines, 64
  antibiotics, 124, 130, 141
  ATG16L1 autophagy gene, 31–32
  AZA/6-MP
    adverse events, 99–100
    induction and maintenance therapy, 94, 96–97
    metabolite levels monitoring, 98–99
    TPMT genotype, 98–99
certolizumab pegol, 115
CIR formulation, 77
clinical entity, 18
colon, 257
  colorectal cancer, 268–269
cost, 297
CT enterography
  capsule endoscopy, 213–214
  extraenteric complications, 211–212
  luminal and extraluminal evaluation, 209
  strictures, 211
cyclosporine A, 102–103
definition, 182
descriptive epidemiology, 19
esophagus, 256
family history, 19
fistulizing/perianal disease, 183
gastric antrum, 256
IBD5 gene, 30
ICD–9 codes, 303
ileum, 257
IL23R gene, 31
maintenance therapy, 307
methotrexate, 100–101
natalizumab, 115–116
Nod2 gene, 28–29
nutrition therapy, 124, 132–133, 143–144
oral contraceptives, 21
perianal inflammatory disease, 208
5p13 gene, 32
prebiotics, 124–125, 136
probiotics, 124, 126, 138–139
risk factors, 182
strictureplasty
complication, 168
complications and long-term results, 169
Finney strictureplasty, 167
Heineke-Mikulicz strictureplasty, 167
indication, 168
Michelassi strictureplasty, 167
systemic agents, 79–81
topical agents, 77–79
Crohn’s disease activity index (CDAI), 308
Crohn’s Trial of the Fully Human Antibody
Adalimumab for Remission and
Maintenance (CHARM), 309
CT colonography, 245
Current procedural terminology (CPT), 298
CYA. See Cyclosporine A
Cyclosporine A (CYA)
CD, 102–103
UC, 103–104
Cytomegalovirus superinfection (CMV), 262

D
Depo-Provera®, 197
Disease activity indices, 217
Double-balloon enteroscopy (DBE)
antegrade approach, 237, 238
CD strictures dilation, 239
vs. CE, 237–238
complication, 240
diagnostic yield, 239
distal ileum, ulcerations, 238, 239
retrograde approach, 238–239
SB Crohn’s management, 239–240
Dysplasia. See also Colorectal cancer
chromoendoscopy, 271, 272
confocal laser endomicroscopy, 272
Crohn’s disease, 268–269
invisible and visible, 270
management, 270
narrow band imaging, 272, 273
strictures, 271
surveillance colonoscopy, 271
ulcerative colitis, 266–268

Endoscopic retrograde cholangiopancreateography (ERCP), 221
Enema, 75–76
Enteral nutrition, 138
Enteroclysis, 214
Enzyme-linked immunoadsorbent assays (ELISA), 179

F
Fecal diversion
adjustment of life, 291–292
complications
irritant contact dermatitis, 289
parastomal hernia, 291
peristomal candidiasis, 289–290
peristomal pyoderma gangrenosum, 290–291
risk factors, 288–289
day to day management, 286–288
life satisfaction score, 292
pouching system
classification, 285
closed-end pouches, 286
ostomy products, 286, 287
skin barrier, 285
wear time, 285
pre operative patient preparation, 284
stoma
creation, 283
function, 284
location, 282–283
WOC nurse, 282
Fertility, 197–198
Finney strictureplasty, 167
Firmicutes, 45
Fistulas
classification, 218
Crohn’s disease, 217
infliximab, 220
perianal disease, 217
Fistulography, 217

Genetics
ATG16L and IRGM, 31–32
future development, 34–35
gene-wide association studies, 30–31,
33–34
HLA class II MHC genes, 30
IBD5 gene, 30
IL23R, 31
IL–10 receptor, 29
Genetics (cont.)
JAKMIP1 and LOC285484 gene, 33
multidrug-resistance gene, 29
MyoIXb gene, 29
NOD1 gene, 29
NOD2 gene, 28–29
5p13, 32
pharmacogenetics, 28
4p16.1, 17q11 and 17q23, 33
SNP rs1793004, 33
TLR gene, 29
Wellcome Trust Case Control Consortium, 32

H
Health-related quality of life (HRQOL), 308–310
Heineke-Mikulicz strictureplasty, 167
Hepato-splenic T cell lymphoma (HSTCL), 157
Homeostasis, 44
Hydrocortisone, 75
Hypoxanthine guanine phosphoribosyltransferase (HPRT), 185

I
Ileal pouch-anal anastomosis (IPAA), 156, 181–182
Ileoanal anastomosis
biopsy, 173
procedure, 171–172
risk factor, 172
stapled technique, 172
Immunogenicity, 112–113
Immunomodulators
AZA and 6-MP
Crohn’s disease, 94, 96–100
mechanism of action and metabolism, 94, 96
randomized-controlled and retrospective trials, 95
ulcerative colitis, 97–98
CYA, 102–104
MMF, 104–105
MTX
adverse events, 102
Crohn’s disease, 100–101
UC, 101–102
tacrolimus, 104
thalidomide, 105–106
6-thioguanine, 105
thiopurines and methotrexate, 95

Immunoregulation
acquired immune system, 49
Th17 pathway, 49–50
TL1A/DR3/Dr3, 50
Indefinite dysplasia (IND), 270
Indeterminate colitis, 20–21, 180
Infectious colitis, 261
Inflammatory bowel disease (IBD). See also
Crohn’s disease; Ulcerative colitis
agile patency capsule, 237
biological therapy, 9 (see also Biological therapy)
capsule endoscopy (see Capsule endoscopy)
characteristics, 19–20
concepts, twentieth century, 4
cortisone, 6
cyclosporine A, 7–8
DBE (see Double-balloon enteroscopy)
eye antibacterial era, 5
eye clinical-related observations, 8
economics
annual treatment costs, 305
cost simulation, 297
cost-utility analysis, 306
Crohn’s maintenance therapy, 307
healthcare utilization and costs, 306
hospitalization cost, 298
ICD–9 codes, 298
incremental cost effectiveness ratio, 307
indirect costs and disability, 300–302
infliximab, 299–300
logistic regression analysis, 299
medical claims database, 297
medical consumer price index, 300
PharMetrics database analysis, 298
endoscopic mucosal imaging techniques
(see Endoscopic mucosal imaging techniques)
epidemiological changes
1950–1975, 19–20
1975–2000, 20–21
2000 and onwards, 21–22
reasons for, 17–18
up to 1950, 18
fecal calprotectin, 234
fecal lactoferrin, 234
incidence, 8, 22
indeterminate colitis, 20–21
interleukin 2 inhibitors, 9, 10
6-mercaptopurine (6-MP), azathioprine, 7
oral tolerance, 9, 11
pathogenesis
adherent-invasive E. coli (AIEC), 46
animal models, 42
autophagy, 48
bacterial flora, 52
card15, 47–48
clinical observations, 48–49
commensal flora, 43–45
defensins, 47
diversity, 51–52
dysbiosis, 45–46

Index

pathology

Index

animal models, 42
autophagy, 48
bacterial flora, 52
card15, 47–48
clinical observations, 48–49
commensal flora, 43–45
defensins, 47
diversity, 51–52
dysbiosis, 45–46

Index

genetic associations, 43

Index

innate immunity, 52

Index

Th17 pathway, 49–50
TL1A/DR3/DcR3, 50

Index

Index

radiology

Index

CT colonography, 245
CTE, 242–244
MR colonography, 245
MRE, 244–245

Index

resource utilization

Index

biological therapies, 304
infliximab, 303
medical costs, 302
NHDS data, 303
surgical rates, 304

Index

Salofalk, 6

Index

serologic markers

Index

anti-CBir1, 233
anti-I2, 233
anti-OmpC, 233
ASCA, 232
benefit, 234
cautions, 233
combination markers, 233
pANCA, 233

Index

smoking, 21

Index

sulphonamides, 5

Index

therapy

Index

therapeutic agents discovery pathways, 9

Index

therapeutic possibilities, 11

Index

therapeutic problems, 3–4
twenty-first century, 9–10
tumor necrosis factor α (TNF-α) antibody

Index

I, 8

Index

Infliximab, 113–115, 201, 220, 300, 303

Index

Intestinal commensal flora, 123–124

Index

abnormal composition

Index

adherent-invasive Escherichia coli, 46
dysbiosis, 45–46
molecular techniques, 45
antimicrobial defense mechanism, 43–44
defective immunoregulation, 49–50
defective microbial clearance (see

Index

Microbial clearance)

Intestinal inflammation, 124

Index

Intestinal resection, 166–167

Index

Irritant contact dermatitis, 289

Index

Ischemia, 260

Index

L

Index

Laparoscopic ileocolectomy, 170

Index

Laparoscopic surgery

Index

Crohn’s disease, 169–170

Index

ulcerative colitis, 173

Index

Lialda®, 61, 66

Index

Ligasure® device, 166

Index

Lupron®, 197

Index

Lymphocytic colitis, 262

Index

M

Index

Magnetic resonance cholangiography, 208

Index

Magnetic resonance colonography

Index

colon evaluation, 222

Index
gadolinium-DTPA, 223
noninvasive tool, 222–223

Index

usage, 223

Index

Magnetic resonance enterography (MRE),

Index

214–217, 244–245

Index

Magnification endoscopy, 240–241

Index

Menopause, 203

Index

Mesalamine, 201

Index

adverse effects and safety, 61–62
chemoprophylaxis, 67
Crohn’s disease

Index

5-ASA, 62

Index

Asacol®, 63
meta-analysis, 63–64

Index

Pentasa®, 63
practice guidelines, 64

Index

metabolism and mechanism of action,

Index

60–61
Mesalamine (cont.)
ulcerative colitis
mesalamine formulation, 66–67
optimal dosing, 65–66
remission induction and maintenance, 64–65

Methotrexate (MTX), 201
adverse events, 102
Crohn’s disease, 100–101
UC, 101–102
Michelassi strictureplasty, 167

Microbial clearance
autophagy, 48
card15, 47–48
clinical observations, 48–49
defensins, 47
innate immune system, 46

MMF. See Mycophenolate mofetil
Monoclonal antibody biological agents, 300
6-MP metabolites
leucopenia, 187–188
oxypurinol, 190
6-TGN levels, 187–188
thiopurine treatment, IBD
failure, 188, 189
therapeutic outcomes, 188–190

MTX. See Methotrexate
Mucosal immune system, 44
Mycophenolate mofetil (MMF), 104–105

N
Narrow band imaging (NBI), 241–242, 272
Natalizumab, 115–116, 201, 300, 310
National Cooperative Crohn’s Disease Study (NCCDS), 62
National hospital discharge survey (NHDS) data, 303
National Institute for Health and Clinical Excellence (NICE), 306
Nutritional therapy
Crohn’s disease, 132–133, 143–144
meta analysis, 134–135
pouchitis, 144
ulcerative colitis, 144

O
Olsalazine, 61
Optical coherence tomography (OCT), 242
Ostomy pouching system, 282. See also Fecal diversion
adhesive/hydrocolloid, 285
closed-end, 286

P
Pap smears, 197
Parastomal hernia, 291
Pediatric IBD
bones and growth
bone mineral density, 159–160
defective bone mass accrual, 159
puberty, 158–159
diagnosis
CD and UC differentiation, 155–156
endoscopic evaluation, 154–155
radiographic evaluation, 154
rectal sparing, 155
serological immune markers, 155
two-tiered approach, 153–154
epidemiology, 152
etiopathogenesis, 152–153
quality of life and psychosocial functioning, 160
transition of care, 161
treatment
ACCENT–1 trial, 157–158
corticosteroids and biological therapy, 157
immunomodulator, 158
infliximab, 158
mesalamine-based therapy, 156
mucosal healing, 156
nutritional therapy, 156–157
objectives, 156
REACH trial, 157–158
top-down therapy, 157

Pegylated Antibody Fragment Evaluation in Crohn’s Disease: Safety and Efficacy (PRECISE 2), 309
Pentasa®, 63
Perianal disease
anal endosonography, 218
Crohn’s disease, 183
Crohn’s disease, 217
endoanal coils, 217–218
PAUS, 220
T2-weighted axial MR image, 218, 219
Perinuclear antineutrophil cytoplasmic autoantibodies (pANCA), 233
Peristomal candidiasis, 289–290
Index

Peristomal pyoderma gangrenosum, 290–291
Pfannenstiel incision, 173
PharMetrics database analysis, 298
PillCam SB capsule, 235
Positron emission tomography-CT (PET/CT) advantage, 224
18-fluorodeoxyglucose, 223
noninvasive assessment, disease activity, 209
uses, 224
Pouchitis, 183, 258
antibiotics, 124, 131, 142
nutritional therapy, 144
prebiotics, 138
probiotics, 124, 129, 140
Prebiotics
Crohn’s disease, 124–125, 136–137
IBD, 125
pouchitis, 138
protective commensal bacteria increment, 136
ulcerative colitis, 124–125, 137
Prednisolone, 76–77, 201
Prednisone, 74
Primary sclerosing cholangitis (PSC) cholangiocarcinoma, 221–222
ERCP, 221
MRCP images, 221, 222
probiotics, 124
ulcerative colitis, 221
Prebiotics
Crohn’s disease, 124, 136–137
IBD, 125
pouchitis, 138
protective commensal bacteria increment, 136
ulcerative colitis, 124–125, 137
Prednisolone, 76–77, 201
Prednisone, 74
Primary sclerosing cholangitis (PSC) cholangiocarcinoma, 221–222
ERCP, 221
MRCP images, 221, 222
Probiotics
Crohn’s disease, 126, 138–139
meta analysis, 134–135
pouchitis, 129, 140
ulcerative colitis, 127–128, 139
Pseudomembranous colitis, 261
Q
Quality adjusted life years (QALY), 306–307
Quality of life (QOL), 160, 308–310
R
Radiation colitis, 260
Radiographic techniques
MR colonography
colon evaluation, 222
gadolinium-DTPA, 223
noninvasive tool, 222–223
usage, 223
PET/CT
advantage, 224
18-fluorodeoxyglucose, 223
noninvasive assessment, disease activity, 209
uses, 224
small bowel disease
CT enterography (see CT enterography)
MR enterography, 214–217
Regional ileitis, 18
S
Serological markers
adjunctive test
anti-CBir flagellin, 179
anti-OmpC, 178
ASCA and pANCA, 179
clinical presentation, 178
IgG, 178
meta-analysis, 179
pediatric patients, 179
antiglycan antibodies, 184
natural history and therapeutical response, 183
ulcerative colitis vs. Crohn’s disease
antiacarbohydrate assays, 181
anti-OmpC and anti-I2 antibody, 181–182
flagellin CBir1 antigen, 182
indeterminate colitis/IBDU, 180
Small bowel disease
CT enterography
abnormal mural enhancement, 210
capsule endoscopy, 213–214
extraenteric complications, 211–212
factors, 209–210
histopathological inflammation, 214
indications, 213
mural stratification, 211
neutral contrast agent, 209
role, 211
sensitivity and specificity, 213–214
structure, 211
use of, 213
MR enterography
biphasic agents, 215
enteroclysis, 214–215
oral contrast demonstration, 215–216
T1-and T2-weighted imaging, 215
Solitary rectal ulcer syndrome, 263
Steroids, 74
Stoma. See also Fecal diversion
creation, 283
function, 284
location, 282–283
Strictureplasty
- complication, 168
- controversies and long-term results, 169
- Finney strictureplasty, 167
- Heineke-Mikulicz strictureplasty, 167
- indication, 168
- Michelassi strictureplasty, 167

Sulfasalazine, 59, 198, 200. See also Mesalamine

Suture line dehiscence, 168

Synbiotic treatment, 137

Systemic corticosteroids
- Crohn’s disease
  - induction of remission, 79–80
  - maintenance treatment, 80–81
- ulcerative colitis
  - induction of remission, 75–76
  - maintenance treatment, 76–77

T

Tacrolimus, 104

Thalidomide, 105–106, 201

6-Thioguanine, 105

Thiopurine S methyltransferase (TPMT) test
- enzymatic pathway, 184–185
- genotype vs. phenotype, 185–187

Topical corticosteroids
- Crohn’s disease
  - induction of remission, 77–78
  - maintenance treatment, 78–79
- ulcerative colitis, 75

Total parenteral nutrition (TPN), 136

Total proctocolectomy, 170–171

Transcutaneous perianal ultrasound (PAUS), 220

Tumor necrosis factor (TNF), 50, 112

U

Ulcerative colitis (UC), 41, 59, 180–183, 258
- aminosalicylates
  - mesalamine formulation, 66–67
  - optimal dosing, 65–66
  - remission induction and maintenance, 64–65
- antibiotics, 124, 131, 141–142
- appendectomy, 21
- azathioprine/6-mercaptopurine, 97–98
- cigarette smoking, protective factor, 19, 21
- colorectal cancer
  - backwash ileitis, 267
  - chronic inflammation, 267
  - incidence rate, 266–267
  - primary sclerosing cholangitis, 267
  - risk, 267–268

continent ileostomy, 171

cyclosporine A, 103–104

descriptive epidemiology, 19

epidemiology, 17–18

family history, 19

genome-wide association studies, 33–34

high grade dysplasia, 259

IBD5 gene, 30

ICD–9 codes, 303

ileoanal anastomosis, 171–173

incidence, 18

infliximab, 116

laparoscopic ileal pouch-anal anastomosis, 173

low grade dysplasia, 259

methotrexate, 101–102

nutritional therapy, 144

pancolitis, 19

5p13 gene, 32

PharMetrics database analysis, 298

phenotype, 19

prebiotics, 124–125, 137

prednisone, 74

probiotics, 124, 127–128, 139

systemic agents, 75–77

topical agents, 75

total proctocolectomy, 170–171

V

Video capsule endoscopy (VCE), 154–155

W

Wireless capsule endoscopy, 211

Women with IBD
- breastfeeding, 202
- contraception, 198–199
- fertility, 197–198
- menopause, 203
- menstrual cycle, 196–197
- pap smears, 197
- pregnancy
  - effects of, 199–200
  - effects on, 199
  - surgery, 202
  - treatment, 200–201
- self-image issues, 196
- smoking habit, 195–196
- surgical outcomes, 203

X

Xanthine oxidase inhibitor, 190